The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of several major drugs.
Get Report Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3354
Partnerships, acquisitions, and collaborations with other leading companies for the development of newer products with improved efficacy are part of the growth strategies adopted by a number of players in the Kaposi sarcoma market. For instance, F. Hoffmann-La Roche Ltd launched a new Global Access Program in September 2014 in partnership with the Joint United Nations Program on HIV/AIDS, the President’s Emergency Plan for AIDS Relief, the Clinton Health Access Initiative, and the Global Fund. The program was centered on HIV viral load testing.
High Incidence of HIV/AIDS, Organ Transplants Driving Growth of KS Market
Increased organ transplant procedures are a leading factor driving the Kaposi sarcoma market since the incidence of the cancer is high among patients who have undergone an organ transplant. “Organ transplant patients are given immunosuppressive agents to prevent their body from rejecting the graft. This makes them highly susceptible to Kaposi sarcoma associated herpesvirus (KSHV) infection,” the author of the study explains. The long term use of these agents increases the rate of risk of these patients by more than 100 times compared to the general population.
The high incidence of HIV/AIDS associated Kaposi sarcoma is one of the major factors driving the adoption of HAART therapy, which subsequently fuels the overall KS market.
High Cost of Treatment a Major Drawback
The cost of cancer drugs used for the treatment of Kaposi sarcoma has been on the rise in the past few years, making it difficult for patients to seek treatment. This is a major concern for both the patients and the payers. “The prices of patented drugs have increased by over five times in the past few years in the U.S. and continue to rise,” the TMR analyst comments. For instance, prices of major drugs used for the treatment of KS, such as liposomal doxorubicin, liposomal daunorubicin, or paclitaxel in combination with HAART, have been increasing significantly, making these unaffordable for middle and lower income groups.
Slow but Steady Growth in Store for Kaposi Sarcoma Market
The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in the KS market, expanding at a 2.6% CAGR from 2016 to 2024.
By type of treatment, HAART led the overall Kaposi sarcoma market in terms of revenue, with chemotherapy and immunotherapy poised to register the highest growth rate over the coming years. In terms of region, the global Kaposi sarcoma market was led by North America in 2015 and the MEA region will record the fastest growth by 2024.